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iNTRoDUCTioN
Fibromyalgia is one of the most frequent rheumatologic 
conditions, its main characteristic being diffuse and chronic 
muscle-skeletal pain.
In a study carried on in Brazil, in the city of Montes Claros, 
fibromyalgia was the second most common rheumatologic 
condition observed, after osteoarthritis. In this study a 
prevalence of 2.5% was observed in the population, the 
majority being females, from which 40.8% were between 35 
and 44 years old.1
Besides the painful setting, these patients often complain of 
fatigue, sleep disturbances, morning stiffness, and paresthesia 
on the extremities, subjective edema sensations and cognitive 
disturbances. Association with other comorbidities is often 
found, contributing to the suffering and decline in quality of 
life of these patients. Among the most frequent comorbidities 
found, we can mention depression, anxiety, chronic fatigue 
syndrome, myofascial syndrome, irritable bowel syndrome 
and nonspecific urethral syndrome.2 
These patients use more analgesic therapies and seek 
medical and diagnostic services more often than the normal 
population. Thus, it is not surprising that in the USA their 
annual costs are as high as U$9,573.00, representing 
expenses 3 to 5 times higher than the average population.3 A 
considerable portion of these costs might be saved when the 
patient is properly diagnosed and treated, avoiding unnecessary 
complementary exams and medications useless for his/her 
treatment.4 
Although fibromyalgia has been recognized as a disease 
long ago, it has only been seriously investigated in the 
last three decades. Little is known about its etiology and 
pathogenesis. Up to date, there are no treatments considered 
highly efficacious. 
Fibromyalgia is a syndrome primarily investigated and 
treated by rheumatologists mainly because it involves a 
chronic condition of musculoskeletal pain, but often these 
patients require a multidisciplinary attendance aiming to 
reach a broad and complete approach of their symptoms and 
comorbidities.
In 2004 the Brazilian Society of Rheumatology published 
the first fibromyalgia guidelines, with the goal of guiding the 
diagnosis and treatment of this syndrome.5 
The goal of the SBR 2006-2008 management in this 
work was not only to update the guidelines for treatment 
of fibromyalgia, but also to innovate, by bringing together 
specialists from other medical fields with knowledge about this 
syndrome to reach a consensus about its treatment. 
METHoDoLoGY
The themes reviewed here were divided among three 
categories: 1) Importance of the fibromyalgia diagnosis with 
general recommendations; 2) Pharmacological treatment; 3) 
Non-pharmacological therapeutic modalities. The degrees of 
recommendation and the levels of scientific evidence were 
taken from the Guidelines Project from the Brazilian Medical 
Association.6 
The methodology was based on the BASCE System,7 an 
organizational method developed by the consulting firm Axia.
Bio with the goal of minimizing deviations and bias of the 
results, based in scientific criteria previously established in 
literature. The BASCE System proposes a systematic approach 
for the adaptation of guidelines and consensus generated in 
different scenarios, observing the answer to questions relevant 
to the local scenery, through the presentation of results in an 
explicit and transparent manner, so that the material generated 
has quality and local scientific validity through: 
Broad and systematic search in the medical literature 
for guidelines and consensus regarding a particular disease; 
Structured evaluation (A) of them with participation of 4 or 
more local specialists who make the Selection of the material 
to be used, based in scores; Panel of Consensus and external 
review with another 8 or more local specialists; Structuring 
(E) of the material adapted to the local reality.
This process was divided into two phases.
Phase I: Preparation of the questions that 
would be decided by the consensus group
For that purpose a bibliographic search was done in guideline 
databases, metanalysis and systematic reviews about fibromyalgia.
The literature search at the Pubmed portal was done with 
the following search strategy: (“fibromyalgia”[MeSH Terms] 
OR “fibromyalgia”[All Fields]) AND systematic [sb] AND 
((“1”[PDAT]: “2008/06/13”[PDAT]) AND (English[lang] OR 
Spanish[lang] OR Portuguese[lang])). One hundred and nine 
papers were found, of which 24 were shown to be publications 
that matched the search goals and, later on, were captured in 
their complete format and text (full text). Fifteen papers were 
selected, in its majority metanalysis, and also guidelines.8-22
At Cochrane Library, the term “fibromyalgia” yielded one 
paper in the session of complete metanalysis.23 In the part of 
protocols, two unfinished projects were identified. 
In the NICE (National Institute of Clinical Excellence) 
and OASIS portals typing of the word “fibromyalgia” did not 
result in any articles. In the DARE portal, two relevant abstracts 
of systematic reviews were found. In the National Guideline 
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Clearinghouse, the search for “fibromyalgia” has shown 17 
items, four being guidelines of interest.9,24,26
A group of six rheumatology specialists, considered 
fibromyalgia scholars and researchers (Group I), by indication 
from the Brazilian Rheumatology Society, evaluated the 
guidelines obtained in the research project using a tool 
adequate for this type of score.27 Incorporation of international 
guidelines in the local discussion was evaluated based on the 
criteria established by the AGREE Collaboration (Appraisal of 
Guidelines Research and Evaluation), which allow evaluation 
and comparison among different guidelines, supporting, thus, 
the utilization of the best criteria found in each guideline. 
AGREE is a generic tool, applicable to any pathology, 
including the following: diagnostic aspects, promotion of 
health, treatment and other interventions. 
The methodology proposed by AGREE evaluates the 
quality of the statement as well as the quality of some aspects 
intrinsic to the recommendations, divided in six domains: 
Extent and purpose (Global Objective of the orientation norm); 
involvement of the parties (representation of all interested 
parties and potential users), rigidity of the development (the 
process of evidence collection used and the formulation of 
recommendations); clarity and presentation e (Language and 
format), applicability (application of the recommendations 
in terms of organization, behavior and costs) and editorial 
independence (exemption of the recommendations and 
acknowledgements of conflicts of interest). 
Based on this method of evaluation, the guidelines that 
reached a percentage equal or higher than 51% in all domains 
were chosen.8,25,26 These selected guidelines served as basis for 
the preparation of an initial questionnaire for the development 
of the consensus. This initial questionnaire was then evaluated 
and modified by the members of Group I. Other metanalysis 
and systematic reviews that did not go through the AGREE 
method were also evaluated by the Group I specialists, 
who decided for or against their incorporation in the list of 
recommendations to be questioned.
The Group I specialists were alerted that the recommendations 
should be prepared according to their degree of recommendation 
and applicability in Brazil.
Once the preparation of this questionnaire was concluded 
by Group I, we move onto the next phase of the project, that 
is, the voting of these recommendations.
Phase II: Voting
Phase II consisted in a meeting among physicians of several 
specialties who study and treat fibromyalgia, with the purpose 
of voting for or against the statements made by Group I. 
These statements reproduce the findings obtained in the 
studies consulted in the first phase. In order to do that, Group 
II was formed by joining Group I members with specialists 
selected by their respective medical associations, taking into 
consideration their experience and recognition in the treatment 
of the disease in question. Group II was, therefore, composed 
by 30 specialists coming from the following societies: Brazilian 
Rheumatology Society, Brazilian Society for the Study of 
Pain, Brazilian Medical Clinic Society, Brazilian Orthopedics 
and Trauma Society, Brazilian Academy of Neurology and 
Brazilian Association of Physical Medicine and Rehabilitation. 
Voting of the elaborated statements was electronic, and the 
participants were not identified individually, only the group 
results being displayed. At the time of voting all specialists 
were alerted that the recommendations should be evaluated 
according to the degree of recommendation and applicability 
in Brazil.
All recommendations were voted as YES or NO, and, 
according to the BASCE methodology,7 and only those that 
had a voting of YES or NO equal or higher than 70% within 
the group were considered consensual. The statements that 
did not obtain consensus in the first voting were material for 
argumentations between a favorable and an opposing specialist. 
At the end of this debate a new voting took place. The questions 
that did not reach the established percentage after the second 
round of voting were considered as not reaching consensus 
and, therefore, were not included in the recommendations of 
this Brazilian Consensus.
This way, the practices recommended here were those that 
obtained at least 70% consensus and the non-recommended 
were those where at least 70% of the specialists agreed in not 
recommending. The ones that did not reach consensus were 
those where there was not a minimum of 70% agreement for 
or against them.
As documentation, the consensus meeting was filmed and 
also documented through electronic vote.
CAPTURE oF RESoURCES 
The Brazilian Rheumatology Society hired the services of 
the company Axia.Bio for capture of resources, technical 
conduction of the consensus and structuring of the meetings 
of the Brazilian Consensus for the treatment of fibromyalgia.
The resources for the realization of this consensus were 
obtained from the laboratories Mantecorp Chemical and 
Pharmaceutical Industry, Ltd. (Mantecorp Indústria Química 
e Farmacêutica Ltda.), Janssen-Cilag Pharmaceutical Ltd. 
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(Janssen-Cilag Farmacêutica Ltda.), Apsen Pharmaceutical 
(Apsen Farmacêutica) and Pfizer Laboratories Ltd. (Laboratórios 
Pfizer Ltda.). Each of these companies contributed with an equal 
amount, equivalent to ¼ of the costs. The capture of resources 
was a responsibility of the company Axia.Bio, who contacted 
and met with representatives in charge of these companies. 
The name of the specialists involved in this work was kept 
confidential, and any contact between these companies and the 
physicians participating in the consensus was forbidden. This 
way we could guarantee the lack of bias in our results. 
RESULTS
Seventy four questions were voted, and consensus was reached 
in 68 (92%) of these. Only 6 (8%) questions did not obtain 
consensus.
Diagnosis and general recommendations
Fibromyalgia must be recognized as a complex and heterogeneous 
health condition in which there is a disturbance in the processing 
of pain associated with other secondary characteristics (degree 
of recommendation D, level of evidence IV).8
The diagnosis of fibromyalgia is exclusively clinical 
and eventual subsidiary exams might be requested only 
for differential diagnosis (degree of recommendation D) 
(Group I). The diagnosis must be confirmed at the beginning 
of the treatment so that we can clarify to the patient what 
is true and what is false (degree of recommendation D).25 
The patient education is a critical factor for the ideal control 
of fibromyalgia (degree of recommendation B).25 As part 
of the initial treatment, we must provide the patients basic 
information about fibromyalgia and its treatment options, 
educating them about pain control and self-control programs 
(degree of recommendation A).25
A complete understanding of fibromyalgia demands a broad 
evaluation of pain, function and psycho-social context (degree 
of recommendation D, level of evidence IV).8 Besides pain, it 
is important to evaluate the seriousness of the other symptoms 
like fatigue, sleep disturbances, mood disturbances, cognition 
disturbances, and the impact of these on the quality of life of the 
patient (degree of recommendation D).25 There was consensus 
that fibromyalgia does not justify work exclusion (degree of 
recommendation D) (Group I-SBR).
The strategy for the ideal treatment of fibromyalgia demands 
a multidisciplinary approach with a combination of non-
pharmacological and pharmacological treatment modalities. 
The treatment must be worked out, in discussion with the 
patient, according to the intensity of his/her pain, functionality 
and its characteristics, (degree of recommendation A),8,25 being 
important also to take into consideration his/her bio-psycho-
social questions, (degree of recommendation D) (Group I-SBR) 
and cultural questions (degree of recommendation D).26
Chronic pain is a persistent health condition that modifies 
one’s life. The goal is the control, not the elimination (degree 
of recommendation D).26
Drug treatment
Among the tricyclic compounds, amitriptyline and the muscle 
relaxant cyclobenzaprine reduce pain and often improve 
the functional capacity, being, thus, recommended for the 
treatment of fibromyalgia (degree of recommendation A, level 
of evidence Ib).8 Nortriptyline was recommended by the group 
for the treatment of fibromyalgia, as opposed to imipramine 
and clomipramine which were not recommended (degree of 
recommendation D) (Group I SBR).
Among the selective serotonin reuptake inhibitors there 
was a consensus that fluoxetine also reduces pain and often 
improves the functional capacity, being also recommended 
for the treatment of fibromyalgia (degree of recommendation 
A, level of evidence Ib).8 The use of serotonin reuptake 
inhibitors like fluoxetine, in combination with tricyclics, 
is also recommended for the treatment of fibromyalgia 
(degree of recommendation B).25 The isolated use of other 
serotonin reuptake inhibitors like sertraline, paroxetine, 
citalopram and escitalopram, was not recommended (degree 
of recommendation D) (Group I SBR).
Among the anti-depressives that block serotonin and 
noradrenalin reuptake, duloxetine and milnacipran were 
recommended for reducing pain and often improving the 
functional capacity of patients with fibromyalgia (degree 
of recommendation A, level of evidence Ib).8 There was no 
consensus as to the utilization of venlafaxine in patients with 
fibromyalgia (degree of recommendation D) (Group I SBR).
Moclobemide, an anti-depressive MAO inhibitor, was 
recommended for the treatment of fibromyalgia for reducing 
pain and often improving the functional capacity of patients 
with fibromyalgia (degree of recommendation A, level of 
evidence Ib).8
There was no consensus as to the utilization of trazodone 
in patients with fibromyalgia (degree of recommendation D) 
(Group I SBR).
The dose of all anti-depressives must be individualized 
and any concomitant mood change must be treated (degree of 
recommendation D).25
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The anti-Parkinson medication pramipexole was also 
recommended for the treatment of fibromyalgia to reduce pain 
(degree of recommendation A, level of evidence Ib),8 being 
specially indicated in the presence of sleep disturbances and 
restless legs syndrome (degree of recommendation A).25
Simple analgesics and light opioids might be also 
considered for the treatment of fibromyalgia, as opposed to 
the potent opioids, which were not recommended (degree of 
recommendation D, level of evidence IV),8 Tramadol was 
recommended for treating pain in fibromyalgia (degree of 
recommendation A, level of evidence Ib).8 Its association 
with paracetamol was considered effective in the treatment of 
fibromyalgia (degree of recommendation B).25 
Tropisetron was also recommended for treating pain in 
fibromyalgia (degree of recommendation A, level of evidence Ib).8 
Among neuromodulating drugs, gabapentine (degree of 
recommendation A),22 and pregabaline were recommended. 
This last one was considered efficacious in reducing pain in 
patients with fibromyalgia (degree of recommendation A, 
level of evidence Ib).8 On the other hand, topiramate was not 
recommended (degree of recommendation D) (Group I SBR).
Corticosteroids should not be used (degree of recommendation 
D, level of evidence IV).8 Non-steroidal anti-inflammatory 
drugs must not be used as first line medication in patients with 
fibromyalgia (degree of recommendation A).25
Zoplicone and zolpidem were recommended for the 
treatment of sleep disturbances in fibromyalgia (degree of 
recommendation D) (Group I SBR).
Clonazepam, tinazidine and alprazolam were not 
recommended for use in fibromyalgia (degree of 
recommendation D) (Group I SBR).
Non-medical treatment
Patients with fibromyalgia must be advised to undertake 
musculoskeletal exercises at least twice a week (degree of 
recommendation B),25 Individualized programs of aerobic 
exercises might be beneficial to some patients (degree of 
recommendation C, level of evidence IIb),8 who must be 
advised to undertake moderately intense aerobic exercises 
(60-75% maximum cardiac frequency age-adjusted ([210 
minus the patient’s age]) twice or three times a week (degree 
of recommendation A),25 reaching the point of light resistance, 
not the pain threshold, avoiding this way the pain induced by 
the exercise. This is particularly important in the subgroup of 
individuals with articular hypermobility (degree of evidence 
B),25 The exercise program must start at a level below the 
patient’s aerobic capacity and progress in frequency, duration 
or intensity as soon as his/her conditioning level and strength 
increase. The progression of exercises must be slow and 
gradual (degree of recommendation D)25 and patients should be 
encouraged to maintain continuity to retain the gains induced 
by the exercises (degree of recommendation B).25 
Individualized stretching programs (degree of 
recommendation D) (Group I SBR) or muscular strengthening 
ones might also be beneficial to some patients with fibromyalgia 
(degree of recommendation C, level of evidence IIb).8 
Other therapies like rehabilitation and physical therapy 
or relaxation might be used in the treatment of fibromyalgia, 
depending on the necessities of each patient (degree of 
recommendation C, level of evidence IIb)8.
Cognitive-behavioral therapy is beneficial to some patients 
with fibromyalgia (degree of recommendation D, level of 
evidence IV).8 Psychotherapeutic support might be also, used 
in the treatment of fibromyalgia, depending on the necessities 
of each patient (degree of recommendation C, level of evidence 
IIb).8
There was no consensus on the indication of treatments with 
clinical support as balneotherapy (degree of recommendation 
A)25 or acupuncture (degree of recommendation C).25 
There was consensus in not recommending hypnotherapy, 
biofeedback, chiropractic manipulation and therapeutic 
massage for pain release in fibromyalgia (degree of 
recommendation B).25
Other therapies like Pilates, GPR/RPG (global postural re-
education) and homeopathic treatment were not recommended 
for the treatment of fibromyalgia (degree of recommendation 
D) (Group I There is no scientific evidence that alternative 
therapies like teas, orthomolecular therapies, crystals, 
chromotherapy and Bach floral remedies, among others, 
are efficacious (degree of recommendation D) (Group I 
SBR). There is also no scientific evidence that infiltrations 
of painful points in fibromyalgia are efficacious (degree of 
recommendation D) (Group I SBR).
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